Epidemiology of porocarcinoma in England 2013–2018: A population-based registry study

Jilse Joshy, Birgitta van Bodegraven, Khaylen Mistry, Paul Craig, Neil Rajan, Sally Vernon, Nick J. Levell, Zoe C. Venables

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
3 Downloads (Pure)

Abstract

Background: Porocarcinoma (PC) is a cutaneous malignancy that differentiates towards (possibly arises from) the sweat ducts and glands. Lack of histological diagnostic markers makes clinical and pathological diagnosis complex. The limited data available suggest the incidence is increasing; however, this remains to be established in national epidemiological studies.

Objectives: To report the incidence, treatment and survival of patients with PC in England from 1 January 2013 to 31 December 2018 using national cancer registry data.

Methods: PC diagnoses in England during 2013–2018 were identified from the National Disease Registration Service using morphology and behaviour codes. These were registered from routinely collected pathology reports and cancer outcomes and services datasets. The 2013 European age standardized incidence rates (EASRs), Kaplan–Meier all-cause survival and log-rank test were calculated.

Results: In total, 738 tumours (396 in males and 342 in females) were diagnosed. The median age at diagnosis was 82 years old (interquartile range 74–88). The most frequently affected site were lower limbs (35.4%), followed by the face (16%). The majority of the cohort received surgical excision (73.0%). The Kaplan–Meier all-cause survival was 45.4% at 5 years, which was lower than in previous studies. The EASR for the whole population was 0.25 [95% confidence interval (CI) 0.23–0.27] per 100 000 person-years (PY)]. PC incidence rates in the East of England (EASR of 0.54, 95% CI 0.47–0.63 per 100 000 PY) were three times higher than the South West (EASR of 0.14, 95% CI 0.10–0.19 per 100 000 PY) where the regional rates were the lowest.

Conclusions: This study shows that there is large variation in the EASRs of PC across England. This may reflect differences in how PC is diagnosed and registered in different regions in England. These data support national assessment of the management of PC, which will inform future studies and guideline development.
Original languageEnglish
Pages (from-to)770–777
Number of pages8
JournalClinical and Experimental Dermatology
Volume48
Issue number7
Early online date1 Apr 2023
DOIs
Publication statusPublished - Jul 2023

Cite this